[Special Stock] HEM Pharma Partners with Harvard... Global No.1 Amway's First Investment in Asia Increases

HEM Pharma is showing strong performance. This is interpreted as being influenced by the news that it is collaborating with Harvard Medical School to build a microbiome data analysis platform utilizing artificial intelligence (AI) technology.

As of 10:41 AM on the 10th, HEM Pharma is trading at 13,780 KRW, up 16.98% compared to the previous day.

According to industry sources, HEM Pharma announced on the same day that it is partnering with Professor Shin-Ho Do of Harvard Medical School to build a microbiome data analysis platform using AI technology. The platform, named 'MINERVA' (Microbiome Network Research and Visualization Atlas), which HEM Pharma and Professor Do are developing, uses large language models (LLM) to analyze and database approximately 120,000 microbiome-related papers from the U.S. National Institutes of Health (NIH).

Professor Do is the director of the Medical Imaging Analysis Center at Massachusetts General Hospital (MGH) and a leading scholar researching AI-integrated medical devices and healthcare technologies in the healthcare market. HEM Pharma and Professor Do plan to develop MINERVA into a personalized healthcare platform. Through MINERVA, it will be possible to identify which specific microbiomes are associated with certain diseases, and expand this into microbiome data-based treatment research for obesity, diabetes, autism, and other conditions.

Meanwhile, Hanyang Securities evaluated HEM Pharma as a company in which Amway, the global No.1 network marketing company, made its first equity investment in Asia, and expects growth similar to that of Kolmar BNH.

Byung-Yong Oh, a researcher at Hanyang Securities, said, "HEM Pharma is a probiotics company that signed a 20-year exclusive sales contract with Amway and is one of only three global microbiome companies."

Researcher Oh emphasized that HEM Pharma projects sales of 12.2 billion KRW in 2024, 26.7 billion KRW in 2025, 55.7 billion KRW in 2026, and 89.6 billion KRW in 2027.

He added, "According to the company, these figures are very conservative estimates. Since they are based on Amway's sales plans, the visibility is very high. Global exports according to Amway's plans will begin next year."

Researcher Oh noted, "There have been many cases where network marketing showed disruptive power in the stock market," citing the example of Kolmar BNH's sales contract for the health supplement 'Hemohim' with 'Atomy.' He added, "In 2020, when Hemohim's sales began to grow significantly, Kolmar BNH's market capitalization surpassed 2 trillion KRW."